Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | DRD3 | P35462 | 6/20 | 0.47 |
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6614953 | 0.85 | KDM4E (0.40) | CYP1A2CYP2C9CYP2C19ALDH1A1POLB | |
| SCHEMBL4054675 | 0.83 | CHRNB4 (0.53) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL4705658 | 0.82 | DRD2 (0.53) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL4758750 | 0.81 | DRD2 (0.48) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL4051310 | 0.81 | ALDH1A1 (0.51) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL4048748 | 0.81 | DRD2 (0.49) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL4222884 | 0.80 | TMEM97 (0.51) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL4051698 | 0.80 | ALDH1A1 (0.50) | DRD2DRD3HTR2AHTR1AMEN1 | |
| SCHEMBL4046282 | 0.80 | ALDH1A1 (0.50) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL4045253 | 0.79 | ALDH1A1 (0.49) | DRD2DRD3HTR2ADRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421070-B1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-11-26 | — | — | EP | claimed |
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | US | claimed |
| EP-1421070-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | claimed |
| WO-2003018566-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | claimed |
| EP-2020409-A1 | New piperidinyl derivatives as modulators of chemokine receptor activity | AstraZeneca AB (SE) | 2009-02-04 | — | — | EP | disclosed |
| EP-1421070-B1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | US | disclosed |
| EP-1421070-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003018566-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | CCR2, CXCR1, CCR5 | DRD2 245/4885DRD3 164/4885HTR2A 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.